United Therapeutics jumps after Tyvaso shows benefit in lung-scarring disease

United Therapeutics

30/03/2026 12:52

** Shares of drugmaker United Therapeutics UTHR.O jump 15.7% to $604.99 premarket

** Co says its inhaled drug Tyvaso improved lung function in patients with idiopathic pulmonary fibrosis, a rare disease that scars the lungs and makes breathing difficult

** Co says a late-stage study met its main goal, showing better lung capacity and lower risk of the disease worsening versus placebo

** Results were consistent across patients, including those on other treatments and with different smoking histories; no new safety issues seen, co says

** Says it plans to seek U.S. FDA priority review by end of summer to expand Tyvaso’s use to the lung disease; similar results seen in a second study published in the New England Journal of Medicine

** Shares rose ~38% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))